Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Approves Real-Time Release NDAs As Agency, Early Adopters Promote PAT

This article was originally published in The Gold Sheet

Executive Summary

Real-time release has arrived with FDA approval of two NDAs that rely on process analytical technology instead of end-product testing for release to market. Merck shares its experience with PAT-based real-time release at IFPAC meeting, while FDA officials express disappointment that pharmaceutical industry has not embraced PAT more broadly. Research funding, agenda explored. Business case made. Sterility concerns raised. Legacy opportunities explored

You may also be interested in...

Regulators Encourage Transition from Batch to Continuous Processing

As pharmaceutical manufacturers increasingly look to continuous processing technologies as a way of controlling costs and potentially increasing drug quality, regulators in the U.S. and the European Union are beginning to use more flexible, quality-by-design-like approaches in evaluating these systems.

Industry Applauds US FDA Plans For Novel Excipients Review Pathway, But Urges Refinement

The FDA’s proposal to establish a separate review path for novel excipients draws industry plaudits and requests for fine-tuning.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts